Mejoramiento de la imagen urbana en la ciudad de Chihuahua

La historia de la ciudad es la de su espacio público. Para el caso de Chihuahua la imagen urbana vincula el espacio físico–cultural para la recreación de los habitantes, proporcionando un área verde y limpia acorde a la historia e identidad de la misma. Por necesidades de la población y el uso de suelo que se le da en cuestiones jurídicas a los espacios públicos, normalmente son utilizados como estacionamientos, inclusive los baldíos son convertidos en estacionamientos donde solo se va generando una plancha de concreto que no permite una oxigenación ni un entorno agradable a la población. Como función urbanística, innovar en estos lotes que no tienen uso dentro de la ciudad y que marcan una discontinuidad a la edificación termina por ser un limitante dentro de la imagen urbana y contaminación visual. Como función ecológica se brinda una oxigenación al entorno atenuando construcciones de valor paisajístico con orden y vegetación a una ciudad con identidad tomando en cuenta el espacio a nivel peatonal es decir contemplar la edad de la población para determinar el espacio más apto, el tamaño del lote y sus colindantes para la continuidad de la fachada proporcionando el orden e imagen a una ciudad con espacio suficientes para estacionamientos, espacios verdes, áreas de recreo, áreas de descanso o la unión de estos espacios. Se considera la ciudad y su diseño a nivel peatonal, así como la escala, edades, necesidades de la población y su entorno, con la finalidad de encontrar un espacio público abierto acorde a vii estas necesidades que se presenten; dando prioridad a zonas de valor paisajístico en conjunto con el reglamento de imagen urbana y paisaje del municipio de Chihuahua. Recreación, imagen urbana, patrimonio histórico y cultural son temas primordiales de la ciudad de Chihuahua para efectos del tema de estudio, se consideraron avenidas que cruzaran por la mitad de la ciudad, ya que son vías que comunican de norte a sur a la población, así como transporte externo a la zona urbana, con la finalidad de cuantificar, medir y dimensionar los espacios, lotes o baldíos desperdiciados y en des uso dentro de la mancha urbana, dando un total de 92 zonas en diferentes colonias adjuntas a la Av. Tecnológico, Av. Carlos Pacheco, Bldv. Fuentes Mares y así como las avenidas colindantes a las principales

Mind the (cultural) gap: International news channels and the challenge of attracting Latin American audiences

This article explores the role of cultural proximity in the perception of international news channels in Latin America by focusing on the cases of CGTN (China), RT (Russia) and HispanTV (Iran). Instrumental to the public diplomacy strategies of their home countries, the success of international broadcasters depends on if/whether audiences accept them. Based on a series of focus groups conducted in Mexico and Argentina, this article argues that cultural proximity strongly influences viewers’ aesthetic experience. The findings show that international broadcasters from culturally distant countries bridge the cultural gap by evoking the style of western broadcasters while dissociating themselves from perceived negative images of their own countries of origin. At a deeper level, cultural proximity entails inclusionary and exclusionary processes even within subcultural spheres. Finally, the findings also show how issues of representation can undermine channel identification by audiences

EDUCACIÓN AMBIENTAL Y SOCIEDAD. SABERES LOCALES PARA EL DESARROLLO Y LA SUSTENTABILIDAD

Este texto contribuye al análisis científico de varias áreas del conocimiento como la filosofía social, la patología, la educación para el cuidado del medio ambiente y la sustentabilidad que inciden en diversas unidades de aprendizaje de la Licenciatura en Educación para la Salud y de la Maestría en Sociología de la SaludLas comunidades indígenas de la sierra norte de Oaxaca México, habitan un territorio extenso de biodiversidad. Sin que sea una área protegida y sustentable, la propia naturaleza de la región ofrece a sus visitantes la riqueza de la vegetación caracterizada por sus especies endémicas que componen un paisaje de suma belleza

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac